Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study: simple scan and blood test may reveal who benefits from melanoma immunotherapy

NCT ID NCT06199713

Recruiting now Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy is working or causing side effects. This is an observational study, meaning it does not test a new drug but aims to improve how doctors monitor treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors quickly tell which melanoma patients are responding to immunotherapy and who might need a different approach.
What could go wrong
This is a very small, early-stage observational study (24 people). It is not testing a new treatment, so it won't directly change care. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA MELANOMA STAGE III MELANOMA STAGE IV UNRESECTABLE MELANOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Wisconsin Hospitals and Clinics (UWHC)

    RECRUITING

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.